Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.

Yurlova L, Derks M, Buchfellner A, Hickson I, Janssen M, Morrison D, Stansfield I, Brown CJ, Ghadessy FJ, Lane DP, Rothbauer U, Zolghadr K, Krausz E.

J Biomol Screen. 2014 Apr;19(4):516-25. doi: 10.1177/1087057113518067. Epub 2014 Jan 29.

PMID:
24476585
2.

Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.

Dudgeon DD, Shinde S, Hua Y, Shun TY, Lazo JS, Strock CJ, Giuliano KA, Taylor DL, Johnston PA, Johnston PA.

J Biomol Screen. 2010 Aug;15(7):766-82. doi: 10.1177/1087057110375304. Epub 2010 Jul 16.

PMID:
20639499
3.

Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

Dudgeon DD, Shinde SN, Shun TY, Lazo JS, Strock CJ, Giuliano KA, Taylor DL, Johnston PA, Johnston PA.

Assay Drug Dev Technol. 2010 Aug;8(4):437-58. doi: 10.1089/adt.2010.0281.

4.

A cell-based high-throughput assay for the screening of small-molecule inhibitors of p53-MDM2 interaction.

Li J, Zhang S, Gao L, Chen Y, Xie X.

J Biomol Screen. 2011 Apr;16(4):450-6. doi: 10.1177/1087057111399191.

PMID:
21471462
5.

Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.

Pellegrino M, Mancini F, Lucà R, Coletti A, Giacchè N, Manni I, Arisi I, Florenzano F, Teveroni E, Buttarelli M, Fici L, Brandi R, Bruno T, Fanciulli M, D'Onofrio M, Piaggio G, Pellicciari R, Pontecorvi A, Marine JC, Macchiarulo A, Moretti F.

Cancer Res. 2015 Nov 1;75(21):4560-72. doi: 10.1158/0008-5472.CAN-15-0439. Epub 2015 Sep 10.

PMID:
26359458
6.

Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.

Li Z, Day CP, Yang JY, Tsai WB, Lozano G, Shih HM, Hung MC.

Cancer Res. 2004 Dec 15;64(24):9080-5.

7.

Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.

Palani CD, Beck JF, Sonnemann J.

Invest New Drugs. 2012 Feb;30(1):25-36. doi: 10.1007/s10637-010-9510-7. Epub 2010 Aug 3.

PMID:
20680659
8.

Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.

Noguchi T, Oishi S, Honda K, Kondoh Y, Saito T, Kubo T, Kaneda M, Ohno H, Osada H, Fujii N.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3802-5. doi: 10.1016/j.bmcl.2013.04.094. Epub 2013 May 15.

PMID:
23726030
9.

Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.

Li Q, Lozano G.

Clin Cancer Res. 2013 Jan 1;19(1):34-41. doi: 10.1158/1078-0432.CCR-12-0053. Epub 2012 Dec 21. Review.

10.

A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions.

Lundholt BK, Heydorn A, Bjørn SP, Praestegaard M.

Assay Drug Dev Technol. 2006 Dec;4(6):679-88.

PMID:
17199506
11.

The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans.

Coffill CR, Lee AP, Siau JW, Chee SM, Joseph TL, Tan YS, Madhumalar A, Tay BH, Brenner S, Verma CS, Ghadessy FJ, Venkatesh B, Lane DP.

Genes Dev. 2016 Feb 1;30(3):281-92. doi: 10.1101/gad.274118.115. Epub 2016 Jan 21.

12.

Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.

Barakat K, Mane J, Friesen D, Tuszynski J.

J Mol Graph Model. 2010 Feb 26;28(6):555-68. doi: 10.1016/j.jmgm.2009.12.003. Epub 2009 Dec 14.

PMID:
20056466
13.

Using BRET to study chemical compound-induced disruptions of the p53-HDM2 interactions in live cells.

Mazars A, Fåhraeus R.

Biotechnol J. 2010 Apr;5(4):377-84. doi: 10.1002/biot.200900272.

PMID:
20235143
14.

Stapled peptides with improved potency and specificity that activate p53.

Brown CJ, Quah ST, Jong J, Goh AM, Chiam PC, Khoo KH, Choong ML, Lee MA, Yurlova L, Zolghadr K, Joseph TL, Verma CS, Lane DP.

ACS Chem Biol. 2013 Mar 15;8(3):506-12. doi: 10.1021/cb3005148. Epub 2012 Dec 18.

PMID:
23214419
15.

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.

Patel S, Player MR.

Expert Opin Investig Drugs. 2008 Dec;17(12):1865-82. doi: 10.1517/13543780802493366 . Review.

PMID:
19012502
16.

mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction.

Shiheido H, Takashima H, Doi N, Yanagawa H.

PLoS One. 2011 Mar 15;6(3):e17898. doi: 10.1371/journal.pone.0017898.

17.

Small-molecule inhibitors of the p53-MDM2 interaction.

Vu BT, Vassilev L.

Curr Top Microbiol Immunol. 2011;348:151-72. doi: 10.1007/82_2010_110. Review.

PMID:
21046355
18.

Mdm2 and Mdm4 loss regulates distinct p53 activities.

Barboza JA, Iwakuma T, Terzian T, El-Naggar AK, Lozano G.

Mol Cancer Res. 2008 Jun;6(6):947-54. doi: 10.1158/1541-7786.MCR-07-2079.

19.

Mouse models of Mdm2 and Mdm4 and their clinical implications.

Xiong S.

Chin J Cancer. 2013 Jul;32(7):371-5. doi: 10.5732/cjc.012.10286. Epub 2013 Jan 18. Review.

20.

Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system.

Amaral JD, Herrera F, Rodrigues PM, Dionísio PA, Outeiro TF, Rodrigues CM.

Biochem Pharmacol. 2013 Mar 15;85(6):745-52. doi: 10.1016/j.bcp.2012.12.009. Epub 2012 Dec 19.

PMID:
23261524
Items per page

Supplemental Content

Write to the Help Desk